See more : PlantArc Bio Ltd. (PLNT.TA) Income Statement Analysis – Financial Results
Complete financial analysis of STAAR Surgical Company (STAA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of STAAR Surgical Company, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Sakuma Exports Limited (SAKUMA.BO) Income Statement Analysis – Financial Results
- Ottakringer Getränke AG (OTS.VI) Income Statement Analysis – Financial Results
- CaliPharms, Inc. (KGET) Income Statement Analysis – Financial Results
- Uscom Limited (UCM.AX) Income Statement Analysis – Financial Results
- Budweiser Brewing Company APAC Limited (1876.HK) Income Statement Analysis – Financial Results
STAAR Surgical Company (STAA)
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.42M | 284.39M | 230.47M | 163.46M | 150.19M | 123.95M | 90.61M | 82.43M | 77.12M | 74.99M | 72.22M | 63.78M | 62.77M | 54.96M | 75.35M | 74.89M | 59.36M | 56.28M | 51.30M | 51.69M | 50.46M | 48.25M | 50.24M | 53.99M | 59.00M | 54.20M | 42.50M | 42.20M | 34.70M | 27.40M | 20.10M | 10.20M | 4.30M | 4.50M | 4.50M | 6.80M |
| Cost of Revenue | 69.76M | 61.01M | 51.84M | 45.10M | 38.23M | 32.44M | 26.33M | 24.06M | 24.40M | 26.16M | 21.91M | 19.49M | 20.40M | 19.88M | 33.45M | 34.79M | 30.10M | 29.85M | 27.52M | 25.54M | 22.62M | 24.10M | 28.20M | 22.60M | 18.70M | 14.10M | 6.80M | 7.90M | 6.90M | 4.80M | 3.10M | 2.40M | 2.00M | 2.00M | 7.20M | 8.00M |
| Gross Profit | 252.65M | 223.38M | 178.64M | 118.36M | 111.95M | 91.51M | 64.28M | 58.37M | 52.72M | 48.82M | 50.31M | 44.29M | 42.37M | 35.08M | 41.89M | 40.11M | 29.27M | 26.43M | 23.79M | 26.14M | 27.84M | 24.15M | 22.03M | 31.39M | 40.30M | 40.10M | 35.70M | 34.30M | 27.80M | 22.60M | 17.00M | 7.80M | 2.30M | 2.50M | -2.70M | -1.20M |
| Gross Profit Ratio | 78.36% | 78.55% | 77.51% | 72.41% | 74.54% | 73.83% | 70.94% | 70.81% | 68.36% | 65.11% | 69.67% | 69.44% | 67.50% | 63.82% | 55.60% | 53.55% | 49.30% | 46.97% | 46.36% | 50.58% | 55.17% | 50.05% | 43.86% | 58.14% | 68.31% | 73.99% | 84.00% | 81.28% | 80.12% | 82.48% | 84.58% | 76.47% | 53.49% | 55.56% | -60.00% | -17.65% |
| Research & Development | 44.40M | 35.98M | 33.86M | 31.92M | 25.30M | 22.03M | 19.12M | 20.29M | 14.76M | 12.36M | 6.71M | 6.44M | 5.87M | 5.72M | 5.89M | 7.94M | 6.71M | 7.08M | 5.57M | 6.25M | 5.12M | 4.02M | 3.80M | 4.22M | 4.30M | 3.60M | 3.90M | 4.10M | 3.30M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 72.32M | 54.74M | 44.14M | 33.91M | 29.31M | 24.29M | 20.67M | 22.25M | 19.60M | 18.48M | 18.81M | 17.79M | 15.99M | 14.08M | 15.71M | 15.73M | 12.95M | 9.34M | 9.34M | 9.34M | 9.34M | 0.00 | 8.75M | 8.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 107.83M | 88.86M | 67.29M | 45.76M | 45.49M | 38.60M | 28.13M | 28.48M | 23.70M | 25.88M | 23.89M | 21.28M | 17.73M | 17.18M | 24.26M | 27.05M | 23.72M | 19.51M | 19.51M | 19.51M | 19.51M | 0.00 | 20.04M | 21.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 180.15M | 143.60M | 111.44M | 79.68M | 74.80M | 62.89M | 48.80M | 50.73M | 43.30M | 44.36M | 42.70M | 39.07M | 33.72M | 31.25M | 39.97M | 42.78M | 36.67M | 33.29M | 29.03M | 30.06M | 29.24M | 25.79M | 28.79M | 43.62M | 27.80M | 25.50M | 19.00M | 17.80M | 15.90M | 13.10M | 14.20M | 11.60M | 12.90M | 6.10M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 1.26M | 967.00K | 396.00K | 703.00K | 715.00K | 628.00K | 470.00K | 759.00K | 381.00K | 486.00K | 822.00K | 0.00 | 700.00K | -238.00K | 9.77M | 0.00 | -331.00K | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| Operating Expenses | 224.55M | 179.58M | 145.30M | 111.59M | 100.10M | 84.92M | 67.91M | 71.02M | 58.06M | 56.85M | 49.61M | 45.51M | 39.59M | 37.68M | 45.62M | 60.49M | 43.39M | 40.04M | 34.60M | 36.30M | 34.36M | 31.26M | 32.59M | 51.57M | 36.30M | 33.50M | 26.40M | 24.20M | 20.70M | 17.10M | 15.10M | 12.40M | 13.50M | 6.60M | 900.00K | 1.50M |
| Cost & Expenses | 294.32M | 240.59M | 197.13M | 156.69M | 138.33M | 117.36M | 94.24M | 95.09M | 82.46M | 83.01M | 71.52M | 65.00M | 59.98M | 57.56M | 79.07M | 95.28M | 73.48M | 69.88M | 62.12M | 61.84M | 56.98M | 55.36M | 60.79M | 74.17M | 55.00M | 47.60M | 33.20M | 32.10M | 27.60M | 21.90M | 18.20M | 14.80M | 15.50M | 8.60M | 8.10M | 9.50M |
| Interest Income | 0.00 | 2.45M | 38.00K | 238.00K | 988.00K | 165.00K | 0.00 | 3.00K | 50.00K | 51.00K | 59.00K | 59.00K | 32.00K | 43.00K | 60.00K | 160.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.45M | 0.00 | 0.00 | 0.00 | 165.00K | 0.00 | 115.00K | 128.00K | 154.00K | 170.00K | 291.00K | 523.00K | 896.00K | 1.33M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 4.51M | 3.64M | 3.10M | 3.70M | 2.46M | 3.35M | 2.89M | 2.40M | 2.46M | 2.15M | 1.96M | 2.27M | 2.41M | 3.74M | 3.64M | 2.51M | 2.37M | 2.47M | 2.69M | 2.90M | 3.10M | 3.62M | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| EBITDA | 33.22M | 48.31M | 36.98M | 9.86M | 15.55M | 9.06M | -277.00K | -9.66M | -3.08M | -5.14M | 3.44M | 1.75M | 5.49M | -379.00K | 364.00K | -17.13M | -12.19M | -10.88M | -7.32M | -7.34M | -3.62M | -4.01M | -6.93M | -16.45M | 8.20M | 11.00M | 12.80M | 12.40M | 8.60M | 6.80M | 2.80M | -3.80M | -10.60M | -3.60M | -2.70M | -1.20M |
| EBITDA Ratio | 10.30% | 17.59% | 17.33% | 5.51% | 10.70% | 7.98% | -1.21% | -11.27% | -2.76% | -6.85% | 4.70% | 2.54% | 8.10% | -0.28% | 0.10% | -22.15% | -18.54% | -20.45% | -17.06% | -14.63% | -6.12% | -4.81% | 1.54% | -21.19% | 13.39% | 19.00% | 23.06% | 27.96% | 23.05% | 21.90% | 10.45% | -63.73% | -244.19% | -313.33% | -60.00% | -19.12% |
| Operating Income | 28.10M | 43.80M | 33.34M | 6.77M | 11.85M | 6.60M | -3.63M | -12.66M | -5.34M | -8.03M | 700.00K | -1.22M | 2.78M | -2.60M | -3.73M | -20.39M | -14.12M | -13.60M | -10.81M | -10.16M | -6.53M | -7.11M | -17.79M | -20.18M | 4.00M | 6.60M | 9.30M | 10.10M | 7.10M | 5.50M | 1.90M | -4.60M | -11.20M | -4.10M | -3.60M | -2.70M |
| Operating Income Ratio | 8.71% | 15.40% | 14.47% | 4.14% | 7.89% | 5.32% | -4.01% | -15.35% | -6.92% | -10.70% | 0.97% | -1.91% | 4.43% | -4.73% | -4.95% | -27.22% | -23.78% | -24.17% | -21.07% | -19.65% | -12.93% | -14.74% | -35.40% | -37.38% | 6.78% | 12.18% | 21.88% | 23.93% | 20.46% | 20.07% | 9.45% | -45.10% | -260.47% | -91.11% | -80.00% | -39.71% |
| Total Other Income/Expenses | 5.60M | 1.75M | -2.04M | 1.50M | 1.17M | 44.00K | 1.34M | 211.00K | -268.00K | -618.00K | 414.00K | 701.00K | -79.00K | -1.08M | -741.00K | -1.29M | -1.04M | 95.00K | 854.00K | -88.00K | -705.00K | -1.01M | 2.99M | -5.30M | -900.00K | -500.00K | 2.40M | 100.00K | 300.00K | 600.00K | 700.00K | 2.70M | -100.00K | 10.00M | 0.00 | -800.00K |
| Income Before Tax | 33.70M | 45.80M | 31.30M | 8.27M | 13.03M | 6.64M | -2.30M | -12.44M | -5.61M | -8.65M | 1.11M | -519.00K | 2.70M | -3.68M | -4.71M | -21.67M | -15.16M | -13.51M | -9.96M | -10.25M | -7.16M | -8.12M | -18.24M | -25.48M | 3.10M | 6.10M | 11.70M | 10.20M | 7.40M | 6.10M | 2.60M | -1.90M | -11.30M | 5.90M | 0.00 | -3.50M |
| Income Before Tax Ratio | 10.45% | 16.11% | 13.58% | 5.06% | 8.67% | 5.36% | -2.53% | -15.10% | -7.27% | -11.53% | 1.54% | -0.81% | 4.31% | -6.70% | -6.25% | -28.94% | -25.53% | -24.00% | -19.41% | -19.82% | -14.19% | -16.84% | -36.31% | -47.20% | 5.25% | 11.25% | 27.53% | 24.17% | 21.33% | 22.26% | 12.94% | -18.63% | -262.79% | 131.11% | 0.00% | -51.47% |
| Income Tax Expense | 12.35M | 6.80M | 6.80M | 2.35M | -1.02M | 1.67M | -157.00K | -315.00K | 928.00K | -253.00K | 716.00K | 1.24M | 1.36M | 432.00K | 1.49M | 1.52M | 843.00K | 1.54M | 1.24M | 1.06M | 1.13M | 8.96M | -3.55M | -6.58M | 900.00K | 2.00M | 4.30M | 3.30M | -100.00K | -2.20M | 100.00K | 500.00K | 100.00K | 2.60M | 800.00K | 200.00K |
| Net Income | 21.35M | 39.67M | 27.51M | 5.91M | 14.05M | 4.97M | -2.14M | -12.13M | -6.53M | -8.39M | 398.00K | -1.76M | 1.35M | 53.00K | -6.20M | -23.20M | -16.00M | -15.04M | -11.18M | -11.33M | -8.36M | -17.16M | -14.83M | -18.90M | 2.20M | 2.40M | 7.40M | 6.90M | 7.50M | 8.30M | 2.50M | -5.10M | -11.30M | 3.50M | -4.40M | -3.80M |
| Net Income Ratio | 6.62% | 13.95% | 11.94% | 3.62% | 9.35% | 4.01% | -2.36% | -14.71% | -8.47% | -11.19% | 0.55% | -2.76% | 2.15% | 0.10% | -8.23% | -30.97% | -26.95% | -26.73% | -21.78% | -21.93% | -16.56% | -35.56% | -29.53% | -35.01% | 3.73% | 4.43% | 17.41% | 16.35% | 21.61% | 30.29% | 12.44% | -50.00% | -262.79% | 77.78% | -97.78% | -55.88% |
| EPS | 0.44 | 0.83 | 0.52 | 0.13 | 0.32 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.18 | 0.57 | 0.50 | 0.55 | 0.84 | 0.21 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| EPS Diluted | 0.43 | 0.80 | 0.50 | 0.12 | 0.30 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.17 | 0.53 | 0.50 | 0.55 | 0.80 | 0.20 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| Weighted Avg Shares Out | 48.52M | 47.99M | 47.21M | 45.61M | 44.49M | 45.16M | 41.00M | 40.33M | 38.43M | 38.09M | 36.71M | 35.26M | 35.43M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.14M | 17.00M | 15.37M | 14.67M | 13.33M | 12.98M | 13.80M | 13.64M | 9.88M | 11.90M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
| Weighted Avg Shares Out (Dil) | 49.43M | 49.38M | 49.46M | 47.95M | 46.90M | 45.26M | 41.00M | 40.33M | 39.26M | 38.09M | 38.61M | 36.25M | 36.88M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.16M | 17.00M | 15.37M | 14.67M | 14.12M | 13.96M | 13.80M | 13.64M | 10.38M | 12.50M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview Net...
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 21, 2023
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended...
STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?
Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.
STAAR Surgical Company (STAA) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Staar Surgical (STAA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
STAAR Surgical Company: Getting Ahead Of Itself In 2023
Shares of implantable lens manufacturer STAAR Surgical Company fell over 55% beginning in August to close out 2022 as Covid lockdowns in China – its largest market – hurt badly. With ~95% of its revenue coming from outside the U.S.,...
Actress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses
LAKE FOREST, Calif.--( BUSINESS WIRE )--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses, today announced a partnership with actress and beauty entrepreneur, Peyton List, to further its mission of bringing EVO Implantable Collamer® Lenses...
Actress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses, today announced a partnership with actress and beauty entrepreneur, Peyton List, to further its mission of bringing EVO Implantable Collamer® Lenses (EVO) to...
STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022
LAKE FOREST, Calif.--( BUSINESS WIRE )--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022. Preliminary net sales...
STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022. Preliminary net sales were approximately...
Why Shares of STAAR Surgical Jumped 23.7% This Week
The new CEO made a major purchase of the company's stock on Monday.
Source: https://incomestatements.info
Category: Stock Reports